Richter Syndrome Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about Richter Syndrome clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaRichter Syndrome
Roswell Park Cancer Institute32 enrolled1 locationNCT06863402
Recruiting
Phase 2

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRichter Syndrome
City of Hope Medical Center20 enrolled2 locationsNCT05672173
Recruiting
Phase 2

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRichter Syndrome
Mayo Clinic27 enrolled3 locationsNCT05388006
Recruiting
Phase 2

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Chronic Lymphocytic LeukemiaRichter Syndrome
Weill Medical College of Cornell University20 enrolled4 locationsNCT04679012
Recruiting
Phase 1

Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation

Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRichter Syndrome+1 more
City of Hope Medical Center23 enrolled1 locationNCT06735664
Recruiting
Phase 2

A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome

Richter Syndrome
University of Birmingham105 enrolled16 locationsNCT03899337